Charles Sinclair
Sr. Director of Translational Sciences, Pioneering Medicines
Charles Sinclair joined Flagship in 2022 as Sr. Director of Translational Sciences, Pioneering Medicines. Charles is responsible for leading Pioneering Medicines' Translational Sciences team to bring forward new medicines across different platforms and therapeutic areas.
Charles brings over 10 years of combined academic and drug discovery research experience in immunology and oncology. Charles began his research career at the MRC National Institute for Medical Research (London, UK) where he undertook a PhD in T-cell homeostasis, focused on T-cell receptor and interleukin-7 receptor signaling. He completed a postdoc at Emory University studying the integration of immuno-metabolic signals by MTOR, in the context of allergic airway inflammation and vaccination. Charles moved into industry at AstraZeneca (Cambridge, UK), serving as a team leader in immuno-oncology and led the discovery of a clinical candidate antisense oligonucleotide targeting FOXP3 (AZD8701, currently in a Ph1a/b trial in oncology). Most recently, he was a discovery program leader at Bristol Myers Squibb, accountable for multiple small molecule programs in targeted oncology, DNA damage response and immuno-oncology. In this role, he was also deeply involved in early target ID/validation governance, nucleic acid therapeutics strategy and BD diligence.
